Paul van de Wiel

Paul van de Wiel is the Chief Operating Officer and Co-Founder of InnoSIGN, a company that focuses on precision oncology using proprietary mRNA-based technology. Prior to founding InnoSIGN, Paul had an extensive career at Philips, where Paul served as General Manager of Molecular Pathway Dx and held leadership roles in molecular diagnostics and precision medicine. With a background in immunology and cancer biology, Paul has been involved in the development of innovative diagnostic tests for infectious diseases and cancer throughout their career in the biotechnology industry.